1. Signaling Pathways
  2. Cytoskeleton
  3. Integrin

Integrin

Integrins, a family of heterodimeric adhesion receptors for diverse extracellular matrices, have consistently been implicated as crucial drivers of ovarian cancer development and progression. A number of the RGD-based members of the integrin family, including α5β1, and αvβ3 or αvβ5 integrins, are markedly elevated in aggressive ovarian tumors. These adhesion receptors appear to promote cell adhesion, survival, motility and invasion during ovarian tumor growth or metastatic progression. Importantly, the functions of these integrins are strongly dependent on the activation of focal adhesion kinase (FAK) and its downstream signaling, including the PI3K/Akt- and Ras/MAPK-dependent pathways.

Integrins are transmembrane proteins and are major receptors for cell-extracellular matrix (ECM) and cell-cell adhesion. Modulation of these molecules, particularly αv integrin family, has exhibited profound effects on fibrosis in multiple organ and disease state. Based on the several studies, the integrins αvβ3, αvβ5, αvβ6, and αvβ8 have been known to modulate the fibrotic process via activation of latent transforming growth factor (TGF)-β in pre-clinical models of fibrosis.

Each integrin is typically formed by the non-covalent pairing of one α subunit, of which, 18 types are known to exist, and one β subunit, of which 8 types are known to exist. Together, 24 distinct heterodimers have been identified to date. The αv subunit can form heterodimers with the β1, β3, β5, β6 or β8 subunits and β1 can associate with many different α subunits from α1 to α11, and αv, indicating that not all theoretically possible α and subunit pairs form. Interestingly, the activation of TGF-β appears to be a common function of multiple αv integrins.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P990857
    Anti-CD54/ICAM-1 Antibody (R6-5-D6)
    Inhibitor
    Anti-CD54/ICAM-1 Antibody (R6-5-D6) is a kind of mouse IgG2a chimeric antibody, targeting to human CD54/ICAM-1. The recommend isotype control of Anti-CD54/ICAM-1 Antibody (R6-5-D6): Mouse IgG2a kappa, Isotype Control (HY-P99978).
    Anti-CD54/ICAM-1 Antibody (R6-5-D6)
  • HY-164360
    αVβ8-IN-1
    Inhibitor
    αVβ8-IN-1 is a αVβ8 integrin inhibitor. αVβ8-IN-1 has been shown to inhibit the growth of tumors such as EMT6, CT26, KPC, and TKCC-10. αVβ8-IN-1 can be used in research related to idiopathic pulmonary fibrosis (IPF), non-specific interstitial pneumonia (NSIP), and tumors.
    αVβ8-IN-1
  • HY-167686
    Variabilin
    Antagonist
    Variabilin (Homopisatin) is a potent RGD-containing antagonist of glycoprotein IIb-IIIa and platelet aggregation inhibitor from the hard tick Dermacentor variabilis. Variabilin potently inhibits platelet aggregation induced by the platelet agonists ADP, collagen, and thrombin receptor peptide SFLLRNP. Variabilin also blocks platelet adhesion to immobilized Fg. In addition, Variabilin inhibits binding of purified human GPIIb-IIIa to immobilized Fg.
    Variabilin
  • HY-120080
    UR-2922
    Antagonist
    UR-2922 is a platelet GPIIb/IIIa antagonist with antiplatelet aggregation and cardiovascular disease inhibition activities. UR-2922 has high affinity for human platelet receptors and has good pharmacokinetic properties, and can be used to inhibit cardiovascular diseases.
    UR-2922
  • HY-116030
    JNJ-26076713
    Antagonist
    JNJ-26076713 is a potent and orally active alpha V integrin antagonist with IC50 values of 2.3 nM and 6.3 nM for alpha(V)beta(3) and alpha(V)beta(5), respectively. JNJ-26076713 inhibits retinal neovascularization.
    JNJ-26076713
  • HY-12290A
    Arg-Gly-Asp-Ser TFA
    Inhibitor
    Arg-Gly-Asp-Ser (TFA) is an integrin binding sequence that inhibits integrin receptor function. Arg-Gly-Asp-Ser (TFA) directly and specifically bind pro-caspase-8, pro-caspase-9 and pro-caspase-3, while it does not bind pro-caspase-1.
    Arg-Gly-Asp-Ser TFA
  • HY-P990207
    Anti-Mouse/Human Integrin β7 Antibody (FIB504)
    Inhibitor
    Anti-Mouse/Human Integrin β7 Antibody (FIB504) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse/human Integrin β7.
    Anti-Mouse/Human Integrin β7 Antibody (FIB504)
  • HY-P10417
    RTDLDSLRTYTL
    Inhibitor
    RTDLDSLRTYTL is an Alpha (v) beta (6) integrin (avb6) inhibitor with high affinity and specificity. RTDLDSLRTYTL binds to avb6 integrin, a peptide sequence that activates cytotoxicity and cytokine production in T cells, such as interferon-gamma. RTDLDSLRTYTL is designed through a chimeric T cell antigen receptor (CAR) so that T cells can be redirected to specifically recognize and attack tumor cells. RTDLDSLRTYTL can be used in the research of cancer immunotherapy and targeted drug development.
    RTDLDSLRTYTL
  • HY-10307A
    Roxifiban acetate
    Inhibitor
    Roxifiban (acetate) is the acetate form of Roxifiban (HY-10307). Roxifiban (acetate) is a platelet glycoprotein (GP) IIb/IIIa receptor inhibitor that can be used in research related to angina.
    Roxifiban acetate
  • HY-P1897
    Fibronectin Active Fragment Control
    Ligand
    Fibronectin Active Fragment Control is an active peptide fragment of fibronectin. Fibronectin is a glycoprotein interacting with integrins.
    Fibronectin Active Fragment Control
  • HY-139137
    N-Acetyl-S-geranylgeranyl-L-cysteine
    Inhibitor
    N-Acetyl-S-geranylgeranyl-L-cysteine is a Methyltransferase inhibitor. N-Acetyl-S-geranylgeranyl-L-cysteine inhibits beta 2 integrin-induced actin polymerization with an IC50 of 45 nM.
    N-Acetyl-S-geranylgeranyl-L-cysteine
  • HY-P5053
    Galacto-RGD
    Galacto-RGD is an RGD analogue that can be coupled with the radioactive isotope 18F and used as an integrin α?β? selective tracer. Galacto-RGD can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    Galacto-RGD
  • HY-139043
    6-B345TTQ
    Inhibitor
    6-B345TTQ is an α4 integrin inhibitor that inhibits α4-Leupaxin interaction. 6-B345TTQ can be used in inflammation research.
    6-B345TTQ
  • HY-P1188A
    LDV-FITC TFA
    LDV-FITC TFA, a fluorescent peptide, is a FITC-conjugated LDV peptide (HY-P2267). LDV-FITC TFA binds to the α4β1 integrin with high affinity (Kd: 0.3 nM and 12 nM for binding to U937 cells in the presence and absence of Mn2+ respectively). LDV-FITC TFA can be used to detect α4β1 integrin affinity.
    LDV-FITC TFA
  • HY-P3227
    Cyclo(Ala-Arg-Gly-Asp-Mamb)
    Inhibitor
    Cyclo(Ala-Arg-Gly-Asp-Mamb) is a selective RGD peptide antagonist and has the potential for Pulmonary arterial hypertension Research.
    Cyclo(Ala-Arg-Gly-Asp-Mamb)
  • HY-P4320
    Cys-Arg-Gly-Asp-Phe-Pro-Ala-Ser-Ser-Cys (Disulfide bridge:cys1-cys10)
    Antagonist
    Cys-Arg-Gly-Asp-Phe-Pro-Ala-Ser-Ser-Cys (Disulfide bridge:cys1-cys10), a decapeptide containing a cyclic RGD active sequence, is an Integrin αIIbβ3 antagonist that inhibits platelet and Adhesion of proMMP-13.
    Cys-Arg-Gly-Asp-Phe-Pro-Ala-Ser-Ser-Cys (Disulfide bridge:cys1-cys10)
  • HY-P1930
    Risuteganib
    Inhibitor
    Risuteganib is a synthetic RGD (arginyl-glycyl-aspartic acid)-class peptide. Risuteganib is an anti-integrin that downregulates oxidative stress and restores homeostasis, and targets three integrin receptors that are implicated in dry age-related macular degeneration (AMD) in order to restore homeostasis in the retina.
    Risuteganib
  • HY-153807
    αvβ6 integrin inhibitor 2
    Inhibitor
    αvβ6 integrin inhibitor 2 is a potent ανβ6 integrin inhibitor with an IC50 of 96.5 nM (WO2020081154A1, example 19).
    αvβ6 integrin inhibitor 2
  • HY-172463
    DSPE-PEG1000-cRGD
    DSPE-PEG1000-cRGD is a PEG compound which composed of DSPE and an αvβ3 targeting peptide (cRGD). cRGD peptide can specifically bind to αvβ3 on the surface of many cancer cells and neovascular cells. DSPE-PEG1000-cRGD can be used for drug delivery.
    DSPE-PEG1000-cRGD
  • HY-19151C
    Fuzapladib calcium
    Inhibitor
    Fuzapladib calcium, an orally active leukocyte-function-associated antigen type 1 (LFA-1) activation inhibitor, is a leukocyte adhesion molecule. Fuzapladib calcium is also a phospholipase A2 (PLA2) inhibitor. Fuzapladib calcium exerts anti-inflammatory effects by inhibiting leukocyte migration into the inflammatory site.
    Fuzapladib calcium
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.